Yuichi Iwaki
Founder presso MEDICINOVA, INC.
Patrimonio netto: 1 M $ in data 29/02/2024
Profilo
Yuichi Iwaki founded MediciNova, Inc. Presently, he is President, Chief Executive Officer & Director at this company and Chief Executive Officer at Avigen, Inc. (a subsidiary of MediciNova, Inc.).
Dr. Iwaki is also Professor at the University of Southern California and Director-Transplantation Immunology at the University of South Carolina School of Medicine.
In the past Yuichi Iwaki occupied the position of Chairman & Acting Chief Executive Officer at AMCOL International Corp.
and Professor at the University of Pittsburgh School of Medicine.
He received a doctorate from Sapporo Medical University School of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
MEDICINOVA, INC.
2.23% | 09/01/2024 | 1 091 933 ( 2.23% ) | 1 M $ | 29/02/2024 |
Posizioni attive di Yuichi Iwaki
Società | Posizione | Inizio |
---|---|---|
MEDICINOVA, INC. | Founder | 26/09/2000 |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Chief Executive Officer | 18/12/2009 |
University of South Carolina School of Medicine | Corporate Officer/Principal | 01/01/1992 |
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | - |
Precedenti posizioni note di Yuichi Iwaki
Società | Posizione | Fine |
---|---|---|
University of Pittsburgh School of Medicine | Corporate Officer/Principal | 01/01/1991 |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Director/Board Member | - |
AMCOL INTERNATIONAL CORPORATION | Chairman | - |
Formazione di Yuichi Iwaki
Sapporo Medical University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
MEDICINOVA, INC. | Health Technology |
Aziende private | 3 |
---|---|
AMCOL International Corp.
AMCOL International Corp. Construction MaterialsNon-Energy Minerals AMCOL International Corp. produces value-added, specialty minerals, and related product. The company was founded on December 30, 1959 and is headquartered in Hoffman Estates, IL. | Non-Energy Minerals |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |